| 摘要 |
This disclosure relates to a novel use of IL-1²-ligand/IL-1 receptor disrupting compounds (herein referred to as "IL-1 beta Compounds"); such as small molecular compounds disrupting IL-1² ligand -IL-1 receptor interaction, IL-1² antibodies or IL-1 receptor antibodies, e.g. IL-1² binding molecules described herein, e.g. anti- bodies disclosed herein, e.g. IL-1² binding compounds or IL-1 receptor binding compounds, and/or RNA com- pounds decreasing either IL-1² ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid ar thritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. |
